SARS-CoV-2 Monoclonal Antibodies Against Spike and Internal Proteins for Therapeutics and Diagnostics

SUMMARY

• As of February 2021, there have been over 107 million cases and over 2 million deaths caused worldwide by the novel virus SARS-CoV-2. Few vaccination and treatment approaches are currently in use with many in development.
• The inventors isolated antibodies specific to spike and internal proteins of SARS-CoV-2 from a unique cohort of COVID-19 patients. The antibodies target non-overlapping epitopes and most afford neutralization activity.
• The product is a panel of over 100 antibodies that bind various SARS-CoV-2 proteins and can be used in both therapeutic and diagnostic applications.
• Antibodies were able to neutralize virus in a live SARS-CoV-2 viral plaque assay with Vero TMPRS22 cells.

FIGURE

Neutralization potency (log10 PFU/ml) of mAbs (n=80) tested by live SARS-CoV-2 virus plaque assay with Vero TMPRS22 cells. Dashed line at x= 6.5 indicates cutoff for neutralization. Percentage of total spike, NP, and ORF8-specific mAbs that displayed neutralization activity. Numbers below each bar chart indicate the number of mAbs tested for neutralization.

ADVANTAGES

ADVANTAGES

• Neutralizing antibodies

• Therapeutic and diagnostic application

APPLICATIONS

• Therapeutic
• Diagnostic

PUBLICATIONS

• Distinct B cell subsets give rise to antigen-specific antibody responses against SARS-CoV-2. 

Mar 1, 2021

Licensing

Patent Pending

Proof of concept

Patrick Wilson